Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18602679 | 0.92 | TSHR (0.35) | TSHRLMNAALDH1A1 | |
| SCHEMBL18933350 | 0.87 | TSHR (0.36) | TSHRLMNAMETAP1 | |
| SCHEMBL1054310 | 0.84 | LMNA (0.37) | TSHRLMNAALDH1A1 | |
| SCHEMBL11824755 | 0.84 | OPRM1 (0.44) | TSHRLMNAALDH1A1 | |
| SCHEMBL819111 | 0.82 | LMNA (0.52) | TSHRLMNAMETAP1ALDH1A1 | |
| SCHEMBL7247072 | 0.82 | LMNA (0.41) | TSHRLMNAALDH1A1 | |
| SCHEMBL19511846 | 0.81 | TSHR (0.43) | TSHRLMNAMETAP1ALDH1A1 | |
| SCHEMBL9918852 | 0.79 | TSHR (0.43) | TSHRLMNAMETAP1ALDH1A1 | |
| SCHEMBL15469686 | 0.79 | TSHR (0.43) | TSHRLMNAMETAP1ALDH1A1 | |
| SCHEMBL598055 | 0.78 | LMNA (0.40) | TSHRLMNAMETAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160024004-A1 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024004-A1 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | HAVCR2, EIF2AK2, NR1H4 | TSHR 4655/4885LMNA 1478/4885METAP1 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.